Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21074265 | 0.83 | MAPT (0.46) | SLC18A3L3MBTL1ALDH1A1 | |
| SCHEMBL20872459 | 0.79 | MCL1 (0.44) | ALDH1A1MGLL | |
| SCHEMBL16099787 | 0.77 | MGLL (0.44) | SLC18A3L3MBTL3L3MBTL1ALDH1A1MGLL | |
| SCHEMBL4200460 | 0.76 | CES2 (0.40) | MGLL | |
| SCHEMBL6954439 | 0.76 | L3MBTL1 (0.44) | SLC18A3L3MBTL1ALDH1A1 | |
| SCHEMBL646545 | 0.74 | ACHE (0.32) | — | |
| SCHEMBL29791844 | 0.73 | SSTR4 (0.33) | — | |
| SCHEMBL28810951 | 0.73 | SSTR4 (0.33) | — | |
| SCHEMBL14194341 | 0.73 | — | — | |
| SCHEMBL20872606 | 0.73 | FAAH (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | MIRALOGX LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | MIRALOGX LLC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022082079-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | METALLO THERAPIES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295125-A1 | METALLOENZYME INHIBITORS FOR TREATING CANCERS, ALZHEIMER'S DISEASE, HEMOCHROMATOSIS, AND OTHER DISORDERS | HMOX1, FECH, SLC40A1 | HTR1F 3875/4885SLC18A3 1543/4885L3MBTL4 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.